Clinical Trial Update: A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study [Phase 2]

View source ↗

Summary

A six-week, randomized, double-blind, placebo-controlled Phase II trial in schizophrenia sponsored by BioLineRx has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: BioLineRx, Ltd. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED